Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacob P Lalezari

Showing results (1-10 of 38) with videos related to

Pageof 4
Sort By:
The AIDS Reader|May 27, 2003
Clinical safety and efficacy of enfuvirtide (T-20), a new fusion inhibitor. A review of the presentation at the satellite symposium "New hope: advancing care in HIV infection" at the 15th annual Association of Nurses in AIDS Care conference, November 2002Jacob P Lalezari
The Journal of the Association of Nurses in AIDS Care : JANAC|January 26, 2006
Enfuvirtide for nurses: answering patient questions on activity, safety, and lifestyle impactEileen Glutzer, Jacob P Lalezari
Drugs of Today (Barcelona, Spain : 1998)|May 19, 2004
EnfuvirtideJacob P Lalezari, Andrew D Luber
Journal of Translational Autoimmunity|March 29, 2021
Case study of a critically ill person with COVID-19 on ECMO successfully treated with leronlimabSohier Elneil, Jacob P Lalezari, Nader Z Pourhassan
AIDS Research and Human Retroviruses|May 30, 2008
An open-label safety study of enfuvirtide injection with a needle-free injection device or needle/syringe: the Biojector 2000 Open-label Safety Study (BOSS)Jacob P Lalezari, Michael Saag, Charles Walworth, et al.
The Journal of Antimicrobial Chemotherapy|May 11, 2007
Preliminary safety and efficacy data of brecanavir, a novel HIV-1 protease inhibitor: 24 week data from study HPR10006Jacob P Lalezari, Douglas J Ward, Susan A Tomkins, et al.
Antiviral Therapy|August 17, 2010
Pharmacokinetics of once-daily etravirine without and with once-daily darunavir/ritonavir in antiretroviral-naive HIV type-1-infected adultsEdwin DeJesus, Jacob P Lalezari, Olayemi O Osiyemi, et al.
Clinical Pharmacology and Therapeutics|June 5, 2004
Assessment of drug-drug interaction potential of enfuvirtide in human immunodeficiency virus type 1-infected patientsXiaoping Zhang, Jacob P Lalezari, Andrew D Badley, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|September 6, 2003
Influence of subcutaneous injection site on the steady-state pharmacokinetics of enfuvirtide (T-20) in HIV-1-infected patientsJacob P Lalezari, Indravadan H Patel, Xiaoping Zhang, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|May 6, 2004
Safety, tolerability, and plasma pharmacokinetics of high-strength formulations of enfuvirtide (T-20) in treatment-experienced HIV-1-infected patientsDavid A Wheeler, Jacob P Lalezari, J Michael Kilby, et al.
Pageof 4

Showing results (1-10 of 38) with videos related to

Sort By:
Pageof 4
The AIDS Reader|May 27, 2003
Clinical safety and efficacy of enfuvirtide (T-20), a new fusion inhibitor. A review of the presentation at the satellite symposium "New hope: advancing care in HIV infection" at the 15th annual Association of Nurses in AIDS Care conference, November 2002Jacob P Lalezari
The Journal of the Association of Nurses in AIDS Care : JANAC|January 26, 2006
Enfuvirtide for nurses: answering patient questions on activity, safety, and lifestyle impactEileen Glutzer, Jacob P Lalezari
Drugs of Today (Barcelona, Spain : 1998)|May 19, 2004
EnfuvirtideJacob P Lalezari, Andrew D Luber
Journal of Translational Autoimmunity|March 29, 2021
Case study of a critically ill person with COVID-19 on ECMO successfully treated with leronlimabSohier Elneil, Jacob P Lalezari, Nader Z Pourhassan
AIDS Research and Human Retroviruses|May 30, 2008
An open-label safety study of enfuvirtide injection with a needle-free injection device or needle/syringe: the Biojector 2000 Open-label Safety Study (BOSS)Jacob P Lalezari, Michael Saag, Charles Walworth, et al.
The Journal of Antimicrobial Chemotherapy|May 11, 2007
Preliminary safety and efficacy data of brecanavir, a novel HIV-1 protease inhibitor: 24 week data from study HPR10006Jacob P Lalezari, Douglas J Ward, Susan A Tomkins, et al.
Antiviral Therapy|August 17, 2010
Pharmacokinetics of once-daily etravirine without and with once-daily darunavir/ritonavir in antiretroviral-naive HIV type-1-infected adultsEdwin DeJesus, Jacob P Lalezari, Olayemi O Osiyemi, et al.
Clinical Pharmacology and Therapeutics|June 5, 2004
Assessment of drug-drug interaction potential of enfuvirtide in human immunodeficiency virus type 1-infected patientsXiaoping Zhang, Jacob P Lalezari, Andrew D Badley, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|September 6, 2003
Influence of subcutaneous injection site on the steady-state pharmacokinetics of enfuvirtide (T-20) in HIV-1-infected patientsJacob P Lalezari, Indravadan H Patel, Xiaoping Zhang, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|May 6, 2004
Safety, tolerability, and plasma pharmacokinetics of high-strength formulations of enfuvirtide (T-20) in treatment-experienced HIV-1-infected patientsDavid A Wheeler, Jacob P Lalezari, J Michael Kilby, et al.
Pageof 4